SEC Says CellCyte Swindled Stem Cell Investors
The U.S. Securities and Exchange Commission has accused biotechnology company CellCyte Genetics Corp. and two of its top executives of fraudulently inflating the company's stock price by telling investors that its...To view the full article, register now.
Already a subscriber? Click here to view full article